Imaging oligometastatic cancer before local treatment.
Authors: Franklin, J.M., Sharma, R.A., Harris, A.L. and Gleeson, F.V.
Journal: Lancet Oncol
Volume: 17
Issue: 9
Pages: e406-e414
eISSN: 1474-5488
DOI: 10.1016/S1470-2045(16)30277-7
Abstract:With the advent of novel treatment strategies to help widen the therapeutic window for patients with oligometastatic cancer, improved biomarkers are needed to reliably define patients who can benefit from these treatments. Multimodal imaging is one such option and should be optimised to comprehensively assess metastatic sites, disease burden, and response to neoadjuvant treatment in each disease setting. These features will probably remain important prognostic biomarkers, and are crucial in planning multidisciplinary treatment. There are opportunities to extract additional phenotypic information from conventional imaging, while novel imaging techniques can also reveal specific aspects of tumour biology. Imaging can both characterise and localise the phenotypic heterogeneity of multiple tumour sites. Novel approaches to existing imaging datasets and correlation with tumour biology will be important in realising the potential of imaging to guide treatment in the oligometastatic setting. In this Personal View, we discuss the current status and future directions of imaging before treatment in patients with extracranial oligometastases.
https://eprints.bournemouth.ac.uk/34606/
Source: PubMed
Imaging oligometastatic cancer before local treatment
Authors: Franklin, J.M., Sharma, R.A., Harris, A.L. and Gleeson, F.V.
Journal: LANCET ONCOLOGY
Volume: 17
Issue: 9
Pages: E406-E414
eISSN: 1474-5488
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(16)30277-7
https://eprints.bournemouth.ac.uk/34606/
Source: Web of Science (Lite)
Imaging oligometastatic cancer before local treatment
Authors: Franklin, J., Sharma, R.A., Harris, A.L. and Gleeson, F.V.
Journal: Lancet Oncology (Science Direct)
Publisher: Elsevier
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(16)30277-7
https://eprints.bournemouth.ac.uk/34606/
Source: Manual
Imaging oligometastatic cancer before local treatment.
Authors: Franklin, J.M., Sharma, R.A., Harris, A.L. and Gleeson, F.V.
Journal: The Lancet. Oncology
Volume: 17
Issue: 9
Pages: e406-e414
eISSN: 1474-5488
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(16)30277-7
Abstract:With the advent of novel treatment strategies to help widen the therapeutic window for patients with oligometastatic cancer, improved biomarkers are needed to reliably define patients who can benefit from these treatments. Multimodal imaging is one such option and should be optimised to comprehensively assess metastatic sites, disease burden, and response to neoadjuvant treatment in each disease setting. These features will probably remain important prognostic biomarkers, and are crucial in planning multidisciplinary treatment. There are opportunities to extract additional phenotypic information from conventional imaging, while novel imaging techniques can also reveal specific aspects of tumour biology. Imaging can both characterise and localise the phenotypic heterogeneity of multiple tumour sites. Novel approaches to existing imaging datasets and correlation with tumour biology will be important in realising the potential of imaging to guide treatment in the oligometastatic setting. In this Personal View, we discuss the current status and future directions of imaging before treatment in patients with extracranial oligometastases.
https://eprints.bournemouth.ac.uk/34606/
Source: Europe PubMed Central
Imaging oligometastatic cancer before local treatment
Authors: Franklin, J.M., Sharma, R.A., Harris, A.L. and Gleeson, F.V.
Journal: Lancet Oncology
Volume: 17
Issue: 9
Pages: E406-E414
ISSN: 1470-2045
Abstract:The term oligometastases is in common clinical use, but remains poorly defined. As novel treatment strategies widen the therapeutic window for patients defined as having oligometastatic cancer, improved biomarkers to reliably define patients who benefit from these treatments are needed.
Multimodal imaging should be optimized to comprehensively assess the metastatic sites, disease burden and response to neoadjuvant treatment in each disease setting.
These features will likely remain important prognostic biomarkers, and are critical in planning multidisciplinary treatment. There are opportunities to extract additional phenotypic information from conventional imaging, while novel imaging techniques can also image specific aspects of tumour biology. Imaging can both characterise and localise the phenotypic heterogeneity of multiple tumour sites. Novel approaches to existing imaging datasets, and correlation with tumour biology, will be important in realizing the potential of imaging to guide treatment in the oligometastatic setting.
This article discusses the current status and future directions of imaging in patients with extracranial oligometastases.
https://eprints.bournemouth.ac.uk/34606/
Source: BURO EPrints